Vertex Pharmaceuticals Incorporated $VRTX Stock: One Wealth Capital Management LLC Cuts Stake

One Wealth Capital Management LLC lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 88.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 443 shares of the pharmaceutical company’s stock after selling 3,473 shares during the quarter. One Wealth Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $232,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Evergreen Capital Management LLC boosted its holdings in Vertex Pharmaceuticals by 0.8% in the 3rd quarter. Evergreen Capital Management LLC now owns 4,257 shares of the pharmaceutical company’s stock worth $2,226,000 after buying an additional 35 shares during the period. Gibbs Wealth Management grew its stake in Vertex Pharmaceuticals by 10.8% in the 3rd quarter. Gibbs Wealth Management now owns 6,074 shares of the pharmaceutical company’s stock valued at $3,176,000 after buying an additional 592 shares in the last quarter. Lantern Wealth Advisors LLC grew its stake in Vertex Pharmaceuticals by 8.0% in the 3rd quarter. Lantern Wealth Advisors LLC now owns 1,350 shares of the pharmaceutical company’s stock valued at $706,000 after buying an additional 100 shares in the last quarter. Lighthouse Financial LLC raised its holdings in Vertex Pharmaceuticals by 52.1% during the 3rd quarter. Lighthouse Financial LLC now owns 9,910 shares of the pharmaceutical company’s stock valued at $5,181,000 after acquiring an additional 3,395 shares during the period. Finally, Fifth Third Wealth Advisors LLC raised its holdings in Vertex Pharmaceuticals by 3.4% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 1,911 shares of the pharmaceutical company’s stock valued at $999,000 after acquiring an additional 62 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Povetacicept delivered positive Phase 3 results. Vertex said the RAINIER trial met all key endpoints in IgA nephropathy, an immune-mediated kidney disease. The results were published in the New England Journal of Medicine and presented at the American Society of Nephrology meeting, supporting the drug’s potential to become an important commercial product. Vertex Pharmaceuticals Posts Positive Phase 3 Results for Povetacicept
• Positive Sentiment: Vertex plans to seek FDA accelerated approval for povetacicept in IgA nephropathy. Regulatory progress could bring a new revenue source closer and reduce the company’s reliance on its cystic fibrosis franchise. Phase 3 RAINIER Results for Povetacicept
• Positive Sentiment: Pipeline diversification is becoming more credible. About 96% of Vertex’s product sales currently come from cystic fibrosis treatments, but povetacicept and inaxaplin could expand the company into kidney disease. Inaxaplin is viewed as a potential blockbuster, adding longer-term growth optionality. Vertex Pharmaceuticals Pipeline Diversification
• Neutral Sentiment: Vertex highlighted its broader kidney-disease research program at ASN Kidney Week 2026, but the presentations do not appear to add a major new financial forecast beyond the povetacicept results. Vertex ASN Kidney Week 2026 Transcript
• Negative Sentiment: Erste Group Bank slightly reduced its EPS forecasts. The firm cut its FY2026 estimate to $16.65 from $16.68 and its FY2027 estimate to $18.97 from $19.09. While the reductions are small, they may weigh on sentiment and highlight near-term earnings uncertainty. Vertex Pharmaceuticals Analyst Estimates

Vertex Pharmaceuticals Trading Down 2.1%

Vertex Pharmaceuticals stock opened at $523.93 on Friday. The firm’s 50 day simple moving average is $523.52 and its 200 day simple moving average is $483.25. The firm has a market capitalization of $132.97 billion, a PE ratio of 30.50, a price-to-earnings-growth ratio of 2.51 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 1-year low of $403.16 and a 1-year high of $560.25.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). The firm had revenue of $3.33 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The business’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.52 earnings per share. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. UBS Group increased their target price on Vertex Pharmaceuticals from $585.00 to $615.00 and gave the stock a “buy” rating in a research report on Monday, September 28th. Royal Bank Of Canada lifted their price target on Vertex Pharmaceuticals from $570.00 to $576.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. Barclays boosted their price objective on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Rothschild & Co Redburn increased their price objective on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Sanford C. Bernstein upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $579.81.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.